AKQA
29.8.2017 08:02:08 CEST | Business Wire | Press release
DIS/PLAY is a digital agency that provides innovation, strategy, user experience, design, and technical development solutions to clients. Employing more than 100 people in Copenhagen and Aarhus, DIS/PLAY’s clients include ECCO, Amnesty International and Vestas.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170828005997/en/
DIS/PLAY’s Copenhagen and Aarhus studios will become part of AKQA, further building AKQA’s European presence and capabilities while providing DIS/PLAY with access to AKQA’s global network and resources.
Steffen Blauenfeldt Otkjær, DIS/PLAY’s CEO said: “AKQA leads globally in creativity and innovation, and DIS/PLAY’S strong technical capabilities make this relationship a natural fit. We are incredibly excited about the opportunities this partnership will create for our clients and team.”
Ajaz Ahmed, AKQA’s CEO said: “It has been a long held aspiration for AKQA to have a studio in Denmark, and thanks to our partnership with DIS/PLAY, that aspiration has become a reality. In the conversations that led to this partnership it quickly became apparent that DIS/PLAY’s ethos mirrors the values of AKQA.”
He added: “Denmark is one of the world’s most influential, beloved and respected nations, consistently taking the top spot on the United Nations World Happiness Report and first place in the Social Progress Index report. We look forward to learning from, and amplifying, this enlightened philosophy.”
Over the past two years, AKQA has added studios in many of the world’s cultural capitals including Sydney, Melbourne, Singapore, São Paulo, Milan, Venice and London. Combined with DIS/PLAY’s additional 110 employees, AKQA now has over 2,100 employees in 23 studios across the USA, Europe, Asia, and Australasia.
About AKQA
A recognised pioneer, AKQA is the global brand experience studio inspired by the imaginative application of art and science. AKQA has grown to become one of the world's most awarded digital agencies. AKQA is part of WPP, the world's largest communications services group. www.akqa.com
About DIS/PLAY
DIS/PLAY is one of the leading digital agencies in Denmark. Specialised in digital strategy, creativity and technology, DIS/PLAY employs 110 people in Copenhagen and Aarhus, who provide both Danish and global companies with quality work on a wide range of platforms - across all digital touchpoints. www.dis-play.dk
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005997/en/
Contact:
AKQA
Gyve Safavi, +44 79 0070 3311
gyve.safavi@akqa.com
or
DIS/PLAY
Jacob
Danstrup, +45 26 85 99 87
jda@dis-play.dk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom